The deal, valued at about $280 million, will see Samsung Biologics America, a U.S. subsidiary, take over the 60,000-liter drug substance plant formerly operated by Human Genome Sciences. The asset transfer is expected to close in the first quarter of 2026.
The Rockville facility, nestled in the heart of Maryland's biotechnology cluster, comprises two manufacturing buildings capable of supporting antibody drug production from clinical trials through commercial scale. Samsung Biologics will retain all 500 employees at the site and inherit existing production contracts, securing a stable pipeline of large-scale contract manufacturing orders.
The acquisition establishes a dual production network linking Samsung Biologics' headquarters in Songdo, South Korea, with the new U.S. base, enabling the company to offer clients greater flexibility and supply chain resilience amid shifting regional regulatory landscapes.
The expanded footprint comes as Samsung Biologics recently bolstered its domestic capacity with an additional 1,000-liter bioreactor at its second plant, bringing total production capacity in Songdo to 785,000 liters across five facilities.
"This landmark acquisition is a testament to our unwavering commitment to advancing global healthcare and bolstering our manufacturing capabilities in the U.S. The investment will enable us to deepen our collaboration with federal, state, and local stakeholders to best serve our customers and partners while ensuring a reliable and stable supply of life-saving therapeutics," said John Rim, CEO of Samsung Biologics.
Regis Simard, president of global supply chain at GSK, said the transaction ensures continued U.S.-based production of critical medicines for American patients. "This deal enables us to further focus on building the agility, capacity and capability needed in our manufacturing network to deliver the next generation of specialty medicines and vaccines," he said.
reporter
Kim Dong-young
davekim0807@ajupress.com
Copyright ⓒ Aju Press All rights reserved.
